Possibility of re-purposing antifungal drugs posaconazole & isavuconazole against promastigote form of Leishmania major
The Indian Journal of Medical Research · 2024
DOI: 10.25259/ijmr_569_2024 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Indian Journal of Medical Research, 2024. Verfasst von Chandra Kanta Bhusal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Aarupadai Veedu Medical College & Hospital, Puducherry, India. Hauptthemen laut MEDLINE: Triazoles, Leishmania major, Pyridines, Antifungal Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background & objectives The emergence of drug resistance in leishmaniasis has remained a concern. Even new drugs have been found to be less effective within a few years of their use. Coupled with their related side effects and cost-effectiveness, this has prompted the search for alternative therapeutic options. In this study, the Computer Aided Drug Design (CADD) approach was used to repurpose already existing drugs against Leishmania major . The enzyme lanosterol 14-alpha demethylase (CYP51), in L. major , was chosen as the drug target since it is a key enzyme involved in synthesizing ergosterol, a crucial component of the cell membrane.
Methods
A library of 1615 FDA-approved drugs was virtually screened and docked with modeled CYP51 at its predicted binding site. The drugs with high scores and high affinity were subjected to Molecular Dynamics (MD) simulations for 100 ns. Finally, the compounds were tested in vitro using an MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide] assay against the promastigotes of L. major .
Results
Computational screening of FDA-approved drugs identified posaconazole and isavuconazole as promising candidates, as both drugs target the CYP51 enzyme in fungi. Molecular dynamics (MD) simulations demonstrated that both drugs form stable complexes with the target enzyme. In vitro studies of posaconazole and isavuconazole against promastigotes of L. major demonstrated significant efficacy, with IC 50 values of 2.062±0.89 µg/ml and 1.202±0.47 µg/ml, respectively. Interpretation & conclusions The study showed that the existing FDA-approved drugs posaconazole and isavuconazole can successfully be repurposed for treating L. major by targeting the CYP51 enzyme, demonstrating significant efficacy against promastigotes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Aarupadai Veedu Medical College & Hospital, Puducherry, India.
- Department of Medical Parasitology, Post Graduate Institute of Medical Education and Research, Chandigarh, Punjab, India.
- Department of Zoology, Panjab University, Chandigarh, Punjab, India.
Zitieren
APA
Bhusal, C. K., Beniwal, P., Singh, S., Kaur, D., Kaur, U., Kaur, S., & Sehgal, R. (2024). Possibility of re-purposing antifungal drugs posaconazole & isavuconazole against promastigote form of Leishmania major. The Indian Journal of Medical Research. https://doi.org/10.25259/ijmr_569_2024
Vancouver
Bhusal CK, Beniwal P, Singh S, Kaur D, Kaur U, Kaur S, et al. Possibility of re-purposing antifungal drugs posaconazole & isavuconazole against promastigote form of Leishmania major. The Indian Journal of Medical Research. 2024. doi:10.25259/ijmr_569_2024
BibTeX
@article{Bhusal2024,
author = {Bhusal, Chandra Kanta and Beniwal, Pooja and Singh, Sarman and Kaur, Davinder and Kaur, Upninder and Kaur, Sukhbir and Sehgal, Rakesh},
title = {Possibility of re-purposing antifungal drugs posaconazole & isavuconazole against promastigote form of Leishmania major},
journal = {The Indian Journal of Medical Research},
year = {2024},
doi = {10.25259/ijmr_569_2024}
}
EUVIMED